Small cell lung carcinoma
Keywords:
lung cancer; , small cell lung cancer; , smoking.Abstract
Introduction: Small cell lung cancer is characterized by rapid growth and the development of distant metastases. It is initially sensitive to chemotherapy and radiation therapy, but most patients relapse within a few months to a year after initial therapy.
Objective: Provide an update on the topic of small cell lung carcinoma.
Methods: A literature review was carried out in PubMed, Science Direct, Google Scholar and SciElo. We excluded those that were not relevant to the objective of this review and selected 30 articles. Articles published in English or Spanish and with scientific validity demonstrated from systematic reviews, meta-analyses, quasi-experimental or experimental studies were included.
Development: Risk factors for lung cancer include: smoking, occupational exposure to asbestos, arsenic, or other substances, or any of the following sources of radiation (radiation therapy to the breast or chest, medical imaging tests, radiation from an atomic bomb, and residence in an environmentally contaminated area), family history and infection with the human immunodeficiency virus. It is possible that this disease is found fortuitously in images of the chest. The most common symptoms at initial presentation are cough that worsens and dyspnea.
Conclusions: Small cell carcinoma predominates in older ages. It has a tendency to metastatic spread. Chemotherapy improves survival, but it is only curative in a few patients.
References
1. Cáncer de pulmón de células pequeñas: Información General y Tratamiento. [página en internet]. Instituto Nacional del Cáncer (PDQ); c2008 [actualizado 22 de abril 2015; [ citado 25 de junio 2024]. Disponible en: http://www.cancer.gov.
2. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. TranslLungCancer Res. 2018[citado 15de junio 2024];7(3):220-233. https://doi.org/10.21037/tlcr.2018.05.06
3. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010 [citado 24 de junio 2024];21(9):1810-1816. https://doi:10.1093/annonc/mdq036
4. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J ThoracOncol. 2015;10(9):1243-1260. DOI: https://doi:10.1097/JTO.0000000000000630
5. Amorín E. Cáncer de pulmón, una revisión sobre el conocimiento actual, métodos diagnósticos y perspectivas terapéuticas. Rev. perú. med. exp. salud pública [Internet]. 2013 [citado 2025 Feb 27] ; 30(1): 85-92. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342013000100017&lng=es.
6. Páramo González DL, Flores Vega YI, Alsina Sarmiento Sd, Alsina Tul LE, Pérez Mederos DR, Flores Rodríguez E, ElejaldeLarrinaga ÁR, Inguanzo Valdés IB, Lamadrid García J, TabioLage A, Gómez Trueba G, Corrales Otero D, Collado Otero JC, Gracia Medina EA, et al. Supervivencia en pacientes con carcinoma de células pequeñas de pulmón tratados en una única institución. RevCubOncol [revista en Internet]. 2021 [citado 19 May 2025]; 19 (2) . Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/106
7. Instituto nacional del cáncer. Sitio oficial de gobierno de los EEUU. Tratamiento del cáncer de pulmón de células pequeñas (PDQ®)–Versión para profesionales de salud[acceso: 19/05/2025]. Disponible en https://www.cancer.gov/espanol/tipos/pulmon/pro/tratamiento-pulmon-celulas-pequenas-pdq
8. Neninger E, del Castillo C, Viada C, Barbán R, Gassiot C, González J. Tratamiento del carcinoma de células pequeñas del pulmón y supervivencia a 5 años. Rev cubana med [internet]. 2008 [citado 17 de mayo 2024];47(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232008000400008&lng=es.
9. Barrionuevo C, Dueñas D. Clasificación actual del carcinoma de pulmón. Consideraciones histológicas, inmunofenotípicas, moleculares y clínicas. Horiz. Med. [Internet]. 2019 [citado 9 de oct 2024];19(4):74-83. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1727-558X2019000400011&lng=es. http://dx.doi.org/10.24265/horizmed.2019.v19n4.11.
10. Casallas A.Inmunohistoquímica y arquitectura genómica en el cáncer pulmonar: perspectiva desde la cirugía de tórax. Rev ColombNeumol [Internet]. 2021;33(1):10-20. DOI: https://doi.org/10.30789/rcneumologia.v33.n1.2021.547
11. García de Vinuesa G. Clasificación anatomopatológica. RevEsp Patol Torac [Internet]. 2017 [citado 9 oct 2024];29(2):13-24. Disponible en: https://www.neumosur.net/files/publicaciones/consensos/CAPITULO-2.pdf
12. Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: a foundation for "next-generation" pathologists and oncologists. Cancers. 2019 [citado 9 oct 2024];11(5). Cancers. 2019 [citado 9 oct 2024];11(5):599. Disponible en: https://doi.org/10.3390/cancers11050599
13. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J ThoracOncol. 2015 [citado 10 oct 2024];10(9):1243-60. Disponible en: https://doi.org/10.1097/JTO.0000000000000630
14. Cabrera LA, Lozano FJ, Blake M, Corona JF, Sánchez R, Pérez SI, et al. Guía de práctica clínica para el manejo del cáncer de pulmón de células pequeñas: enfermedad limitada. Gac. mex. oncol. [revista en la Internet]. 2023 [citado 1 sept 2024];22(1):3-23. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2565-005X2023000100003&lng=es.
15. American CancerSociety. Estadísticas importantes sobre el cáncer de pulmón [Internet]. Atlanta, GA: American CancerSociety; 2024 [citado 2024 Dec 8]. Disponible en: https://www.cancer.org/es/cancer/tipos/cancer-de-pulmon/acerca/estadisticas-clave.html cancer.org | 1.800.227.2345
16. Cayuela A. Mortalidad por cáncer de pulmón en España. Evolución en 25 años. [Internet]. Archivos de Bronconeumología. International Journal of Spanich respiratory society of pulmonology and thoracic surgery. 2023. [citado 2024 Dec 8]. Disponible en: https://www.archbronconeumol.org/en-mortalidad-por-cancer-pulmon-espana--articulo-S0300289608703910
17. Anuario estadístico de salud 2023. [Internet]. Ministerio de Salud Pública de Cuba. 2024. [citado 2024 Dec 8]. Disponible en : https://files.sld.cu/dne/files/2024/09/Anuario-Estad%c3%adstico-de-Salud-2023-EDICION-2024.pdf
18. Clínica Corachán. Cáncer de pulmón: tipos de tumores y principales factores de riesgo. [Internet]. GenesisCare. 2024. [citado 2024 oct 18]. Disponible en: https://corachan.genesiscare.com/cancer-de-pulmon-tipos-de-tumores-y-principales-factores-de-riesgo/
19. Basumallik N, Agarwal M. Small cell lung cancer [Internet]. Treasure Island (FL):StatPearlsPublishing;actualizado julio 2022 [consultado:mayo 2024]. Disponible en: https://www.scielo.org.mx/scielo.php?script=sci_nlinks&pid=S2565-005X202300010000300013&lng=en
20. Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, et al. Small-cell lung cancers in patients who never smoked cigarettes. J ThoracOncol. 2014;9(6):892-6. https://www.scielo.org.mx/scielo.php?script=sci_nlinks&pid=S2565-005X202300010000300017&lng=en
21. Lang C, Lantos A, Megyesfalvi Z, Egger F, Hoda M, Mosleh B, et al. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer. ESMO open. 2022; 7(6), 100631. Disponible en: https://doi.org/10.1016/j.esmoop.2022.100631
22. World Health Organization. Estimated number of incident cases and deaths Mexico, both sexes, all ages. Globocan. 2020 [Internet]. WorldHealthOrganization [consultado:mayo 2024]. Disponible en: https://gco.iarc.fr/today/online-analysis-multi-bars
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maryanis Mosqueda Furones, Dailyvis Chacón Lorenzo, Lourdes María Serra Otero, Ana Marina Chao Fernández, Catherina Catherina Capote Guitian
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
